微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 34.2% | 9.73% | 0.13% | 103/157 | 48.88% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 34.15% | 24.92% | 7.36% | 101/157 | 50.55% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 31.81% | -4.34% | 0.91% | 112/157 | 50.61% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 31.53% | -5.05% | 1.16% | 113/157 | -2.2% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 31.16% | -10.53% | 13.99% | 114/157 | 14.82% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 27.34% | -20.74% | -17.79% | 118/157 | 31.96% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 33.26% | 0.59% | 0.16% | 112/157 | 51.88% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 33.2% | 0.49% | -4.67% | 111/157 | 22.51% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 34.83% | -1.16% | 0.97% | 109/157 | 33.12% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 34.49% | -1.15% | 4.34% | 107/157 | 51.76% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 33.06% | 1.39% | 0.06% | 111/157 | 51.61% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 33.04% | 2.41% | -6.24% | 111/157 | 32.47% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 35.24% | 8.18% | 0.98% | 110/157 | 38.42% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 34.9% | 15.11% | 7.03% | 109/157 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 32.61% | 2.09% | 1.06% | 115/157 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 32.26% | 2.58% | -0.96% | 108/157 | 5.64% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 32.58% | 3.28% | 7.45% | 113/157 | 20.99% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 30.32% | -8.04% | -5.08% | 109/157 | 54.39% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 31.94% | -18.43% | 1.55% | 122/157 | 55.2% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 31.45% | -19.95% | -0.29% | 106/157 | 46.77% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 31.54% | -25.11% | -4.32% | 118/157 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 32.97% | -24.85% | -15.81% | 99/157 | 54.13% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 39.16% | 4.95% | -0.34% | 107/157 | -148.64% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 39.29% | 10.97% | -6.72% | 90/157 | 56.43% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 42.12% | 21.01% | -3.99% | 89/157 | 54.17% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 43.87% | 22.34% | 17.58% | 75/157 | 55.17% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 37.31% | -6.56% | 5.38% | 103/157 | -1242.15% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 35.4% | -10.11% | 1.72% | 86/157 | 55.23% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 34.8% | -11.19% | -2.94% | 92/157 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 35.86% | -12.48% | -10.2% | 82/157 | 51.07% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 39.93% | 26.03% | 1.39% | 95/157 | -211.97% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 39.38% | 32.54% | 0.5% | 71/157 | 54.14% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 39.19% | 55% | -4.35% | 73/157 | 53.53% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 40.97% | 68.02% | 29.32% | 68/157 | 54.16% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 31.68% | -0.97% | 6.63% | 94/157 | 52.55% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 29.71% | -6.03% | 17.53% | 77/157 | 49.09% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 25.28% | -25.63% | 3.68% | 90/157 | 47.91% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 24.39% | -33.86% | -23.78% | 78/157 | 46.94% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 31.99% | -13.59% | 1.17% | 85/157 | 48.46% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 31.62% | -11.47% | -6.98% | 58/157 | 46.19% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 34% | -4.68% | -7.8% | 64/157 | 46.26% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 36.87% | 1.85% | -0.42% | 46/157 | 43.86% | 贝达药业 | 97.01% | 行业排名> |